Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$48.05 USD
+1.09 (2.32%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $48.09 +0.04 (0.08%) 7:14 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
Agios Pharmaceuticals, Inc. [AGIO]
Reports for Purchase
Showing records 281 - 300 ( 306 total )
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
AG-120, Active in IDH1m Solid Tumors, But is it Active Enough?
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Biotechnology: Panic Has Created Some Compelling Opportunities on the Long Side
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Awaiting Clarity from AG-120 and AG-348 Before Getting Constructive
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Biotechnology: 2H15 Catalysts For Key Stocks From Our Research Universe
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Focus Now on the Upcoming EHA Data Deluge
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
IDH Programs Positioned to be the Next Standard-of-Care in IDHm-AML
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Introduction of AG-881 Throws a Curveball,Reiterate Neutral
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Healthcare -Biotechnology: Catalyst Tracker Through Mid-15
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Healthcare: Biotechnology: Its Yogi Berra All Over Again
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.